Castle Biosciences vs Twist Bioscience
Castle Biosciences and Twist Bioscience are similar in size: $344m and $377m of revenue in their latest fiscal years. Twist Bioscience grew faster (20.3% against 3.7%). Castle Biosciences kept more of each dollar of sales as profit: a net margin of -7.0% against -20.6%. Twist Bioscience carries less debt relative to equity (0.0% against 2.2%).
| Latest fiscal year | Castle BiosciencesCSTL, 2025 | Twist BioscienceTWST, 2025 |
|---|---|---|
| Revenue | $344m | $377m |
| Revenue growth | 3.7% | 20.3% |
| Net income | −$24.2m | −$77.7m |
| Operating margin | -12.4% | -36.2% |
| Net margin | -7.0% | -20.6% |
| Return on equity | -5.2% | -16.4% |
| Free cash flow | $28.3m | −$75.6m |
| Cash | $117m | $183m |
| Total debt | $10.2m | $0 |
| Debt to equity | 2.2% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 883 | 979 |
| Market value | $1.07bn | $8.74bn |
| Price vs our value range | — | — |
| Moat score | 32 (Weak) | 11 (Weak) |
| Insider trades, 12 months | 0 buys, 170 sales | 0 buys, 180 sales |